TRAW Traws Pharma, Inc.

Nasdaq www.trawspharma.com


$ 2.06 $ -0.09 (-4.15 %)    

Monday, 17-Nov-2025 15:45:01 EST
QQQ $ 602.24 $ -5.20 (-0.85 %)
DIA $ 466.18 $ -5.48 (-1.16 %)
SPY $ 664.68 $ -6.26 (-0.93 %)
TLT $ 89.11 $ 0.22 (0.25 %)
GLD $ 370.86 $ -4.31 (-1.15 %)
$ 2.08
$ 2.17
$ 2.06 x 100
$ 2.11 x 600
$ 2.04 - $ 2.21
$ 0.97 - $ 19.44
493,951
na
16.62M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 04-01-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-13-2022 03-31-2022 10-Q
16 03-21-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 03-18-2021 12-31-2020 10-K
21 11-16-2020 09-30-2020 10-Q
22 08-12-2020 06-30-2020 10-Q
23 05-15-2020 03-31-2020 10-Q
24 03-27-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 04-01-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-16-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 03-29-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-15-2016 06-30-2016 10-Q
39 05-11-2016 03-31-2016 10-Q
40 03-28-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

-SEC Filing

Core News & Articles

Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development...

Core News & Articles

Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.11) per share. This is a 99.46 percent increase over losses of $(20...

Core News & Articles

Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southe...

Core News & Articles

Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharma...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION